ONCAlert | Upfront Therapy for mRCC

Prostate Cancer VIEW MORE >>

A significant proportion of patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations responded well to treatment with olaparib in a phase II TOPARP-B trial, making olaparib the first targeted therapy to show benefit in this patient population, the Institute of Cancer Research reported in a press release.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.